Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

Principal Investigator

CONTACT INFORMATION

Primary Contact:
Nadeem Mukhtar
(650) 497-8815